Unlike treatment with EGFR-specific and anaplastic lymphoma kinase (ALK)-specific tyrosine kinase inhibitors (TKIs) of advanced NSCLC patients with high levels of CRP, LDH in the serum and poor performance status were found not fit for treatment with nivolumab [78]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.